Zonamax ES 1000mg/500mg Injection is a potent combination antibiotic formulation containing Cefoperazone 1000mg and Sulbactam 500mg, designed for the treatment of a broad spectrum of bacterial infections. Cefoperazone, a third-generation cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, while Sulbactam acts as a beta-lactamase inhibitor, enhancing the efficacy of Cefoperazone against beta-lactamase producing resistant strains. This synergistic combination is effective against a wide range of Gram-positive and Gram-negative pathogens, including strains resistant to other beta-lactam antibiotics. Zonamax ES is indicated for severe infections such as lower respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, septicemia, and gynecological infections. The injectable formulation allows for rapid systemic distribution and is suitable for intravenous or intramuscular administration in hospital settings. Dosage and duration of therapy should be determined based on the severity of infection, patient condition, and susceptibility patterns. Caution is advised in patients with hypersensitivity to cephalosporins or penicillins, and renal or hepatic impairment. Adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and alterations in blood counts. Zonamax ES 1000mg/500mg Injection provides an effective therapeutic option for managing complicated bacterial infections with enhanced beta-lactamase resistance.